• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Cytek Biosciences Inc.

    6/1/26 4:07:56 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTKB alert in real time by email
    SD 1 d123479dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

     

    Cytek Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40632   47-2547526

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    47215 Lakeview Boulevard

    Fremont, California 94538

    (Address of principal executive offices) (Zip code)

    Wenbin Jiang, Ph.D.

    President and Chief Executive Officer

    (877) 922-9835

    (Name and telephone number, including area code, of the person to contact in connection with this report)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1, 2025 to December 31, 2025.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended     .

     

     
     


    Section 1 - Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    This Specialized Disclosure Report on Form SD (the “Form SD”) of Cytek Biosciences, Inc. (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2025 to December 31, 2025. The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified in the Rule are necessary to the functionality or production of those products. The minerals specified in the Rule are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin, and tungsten (collectively, the “3TG Minerals”). These requirements apply to registrants whether or not the 3TG Minerals in their supply chain originated in the Democratic Republic of the Congo or an adjoining country (the “Covered Countries”).

    The following disclosure, in response to the provisions of paragraphs (a) and (b) of Item 1.01 of Form SD, has been made in accordance with the Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule issued by the Division of Corporation Finance of the SEC on April 7, 2017 (the “April 2017 Guidance”). As permitted under the April 2017 Guidance, this Form SD does not address Item 1.01(c) of Form SD.

    Conflict Minerals Disclosure

    Overview

    The Company is a leading cell analysis solutions company advancing the next generation of cell analysis tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The Company’s products include flow cytometry instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.

    This Form SD relates to products of the Company (i) for which 3TG Minerals are necessary to the functionality or production of that product; (ii) that were manufactured, or contracted to be manufactured, by the Company; and (iii) for which the manufacture was completed during 2025. These products consist of the Company’s flow cytometry instruments, including the Cytek Aurora, Cytek Aurora Evo, Cytek Aurora CS, Northern Lights, Northern Lights CLC, DxP Athena and Amnis- and Guava-branded systems for cell analysis, the Cytek Orion system for reagent cocktail preparation and sample loading systems, and related parts and accessories (collectively, the “Covered Products”).

    During 2025, the Company’s manufacturing operations are located in Fremont, California; San Diego, California; Seattle, Washington; Singapore; and Wuxi, China. The Fremont facility manufactured the Cytek Aurora, Cytek Aurora Evo, and Cytek Aurora CS systems, and spare parts; the San Diego facility manufactured reagents; the Seattle facility manufactured Amnis instruments and spare parts; the Singapore facility manufactured Cytek Aurora, Cytek Aurora Evo, Cytek Aurora CS, Northern Lights and Amnis ImageStream systems, and certain reagents and spare parts; and the Wuxi facility manufactures the Cytek Aurora, Cytek Aurora Evo, Cytek Aurora CS, Northern Lights, Guava and Athena instruments, certain reagents and spare parts.

    The Company’s supply chain with respect to the Covered Products is complex, and there are many third parties in the supply chain between the original sources of 3TG Minerals and the ultimate manufacturing of the Covered Products. The Company does not purchase 3TG Minerals directly from mines, smelters or refiners and must, therefore, rely on its suppliers to provide information regarding the origin of the 3TG Minerals that are necessary to the functionality or production of the Covered Products. The Company expects its suppliers to maintain systems of control and transparency over its mineral supply chains. The Company is committed to conducting its business worldwide with respect for human rights and in compliance with applicable laws.

    Reasonable Country of Origin Inquiry

    The Company has, in good faith and after reasonable due diligence, conducted a reasonable country of origin inquiry (“RCOI”) to determine whether 3TG Minerals that are necessary to the functionality or production of its Covered Products originated in the Covered Countries, or whether any of the 3TG Minerals may have been from recycled or scrap sources.


    As an initial step, key personnel in the Company’s manufacturing, supply chain and purchasing functions were asked to evaluate the Company’s products to determine if 3TG Minerals may have been present and potentially necessary to the production or functionality of any product and to create a list of suppliers of components used in Covered Products during the reporting year ended December 31, 2025 (“Suppliers”).

    The Company retained a third-party service provider (“Service Provider”) to assist with data collection and analysis of the information using the Conflict Minerals Reporting Template from the Responsible Minerals Initiative (“CMRT”). The CMRT is a standardized reporting template designed to facilitate the transfer of information through the supply chain regarding mineral country of origin and the smelters and refiners being utilized.

    Through the Service Provider, the Company contacted the Suppliers and conducted a supply-chain survey using the CMRT. Most Suppliers provided “company-level” CMRT responses for all products sold by such Supplier during the reporting year although the Company purchased only a limited subset of such products. The Company reviewed the CMRT responses for completeness, consistency, and accuracy. For components that are not directly manufactured by the Suppliers, the Company relied on the Suppliers to conduct a RCOI to determine whether 3TG Minerals were contained in these components and relied on the CMRTs provided by the Suppliers from their suppliers or manufacturers.

    The Company believes its RCOI process was reasonably designed and performed in good faith. However, there are inherent limitations in the information provided by third parties, including but not limited to: gaps in Supplier and smelter data; errors or omissions by Suppliers or smelters; gaps in Supplier education and knowledge; timeliness of data; public information not discovered during a reasonable search; and Supplier and smelter unfamiliarity with the protocols for identifying and sourcing 3TG Minerals.

    Determination

    Based on this RCOI, the Company has reason to believe that certain 3TG Minerals contained in some Covered Products may have originated in a Covered Country and are not from recycled or scrap sources. Most Suppliers reported that 3TG Minerals either were not present, not sourced from Covered Countries, or were sourced primarily from smelters or refiners certified as “conflict free.” 26 Suppliers have represented that their products contain 3TG Minerals originating from the Covered Countries; however, 11 of these Suppliers further represented that such 3TG Minerals were sourced from smelters or refiners that are either conformant with, or otherwise in compliance with, the Responsible Mineral Assurance Process (“RMAP”) standards or Conflict-Free Smelter Program Assessment Protocols; the remaining 15 Suppliers represented that their response applied company-wide and non-conformant smelters may not be tied to products actually supplied to the Company. In addition, a small number of Suppliers acknowledged the presence of 3TG Minerals without being able to identify their source or the status of the smelters or refiners, or reported sourcing from identified smelters recognized and listed by the Responsible Minerals Initiative’s smelter database but without confirmation of their RMAP status. Some Suppliers failed to respond or provide complete responses notwithstanding multiple requests from the Company. Accordingly, the Company cannot reasonably determine whether 3TG Minerals were included in components from such Suppliers and/or the exact source of 3TG Minerals incorporated into such components, if at all.

    Additional Information

    A copy of this Form SD can be found on our corporate website at www.cytekbio.com. The Company’s website and the information accessible through the website are not incorporated by reference into this Form SD.

    Item 1.02 Exhibit

    None.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

       

    Cytek Biosciences, Inc.

    Date: June 1, 2026

       

    By:

     

    /s/ Wenbin Jiang, Ph.D.

         

    Wenbin Jiang, Ph.D.

         

    President and Chief Executive Officer

    Get the next $CTKB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTKB

    DatePrice TargetRatingAnalyst
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $CTKB
    SEC Filings

    View All

    SEC Form 8-K filed by Cytek Biosciences Inc.

    8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

    6/2/26 4:15:52 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SD filed by Cytek Biosciences Inc.

    SD - Cytek Biosciences, Inc. (0001831915) (Filer)

    6/1/26 4:07:56 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

    SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    5/18/26 6:22:44 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Holder Michael converted options into 1,454 shares, increasing direct ownership by 10% to 16,721 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    5/20/26 6:01:31 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 38% to 22,392 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    5/20/26 5:59:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 22,179 shares and covered exercise/tax liability with 5,532 shares, increasing direct ownership by 0.34% to 4,932,580 units (SEC Form 4) (tax withholding)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    5/20/26 5:56:22 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026

    FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- At CYTO 2026, the industry's premier flow cytometry conference, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) will showcase its expanding portfolio of end-to-end cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer, as well as automation-ready configurations of the Cytek Aurora Evo system. The 39th annual Congress, themed Cytometry: The Next Wave, will spotlight emerging technologies shaping the future of the field. Cytek continues to play a central role in that evolution, advancing high-parameter analysis through innovations designed to increase flexibilit

    6/2/26 5:00:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Reports First Quarter 2026 Financial Results

    FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the first quarter of 2025Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first quarter. On a trailing-12-month basis, recurring revenue represented 35% of

    5/7/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    6/3/25 5:39:17 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by TD Cowen with a new price target

    TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

    5/9/25 8:41:00 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences downgraded by Goldman with a new price target

    Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

    1/31/25 6:59:30 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

    IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

    7/3/25 1:00:00 PM ET
    $CTKB
    $MDXH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Cytek Announces Resignation of Chief Operating Officer Chris Williams

    FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

    9/12/24 3:20:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTKB
    Financials

    Live finance-specific insights

    View All

    Cytek Biosciences Reports First Quarter 2026 Financial Results

    FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to the first quarter of 2025Total recurring revenue, comprised of service and reagent revenues, reached $18.4 million in the first quarter. On a trailing-12-month basis, recurring revenue represented 35% of

    5/7/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generation

    4/23/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of

    2/26/26 4:05:00 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials